Eledon Pharmaceuticals, Inc. Business Acquisition, Pro Forma Net Income (Loss)
Eledon Pharmaceuticals, Inc. (ELDN) reported Business Acquisition, Pro Forma Net Income (Loss) of -$11.79 million for the 12-month period ending 2017-12-31, per its 10-K filed 2019-03-28.
Discontinued › Expense Statement › Operating Expenses
us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss · last filed 2019-03-28
- Eledon Pharmaceuticals, Inc. business acquisition, pro forma net income (loss) for the quarter ending 2017-12-31 was -$2.11M.
- Eledon Pharmaceuticals, Inc. business acquisition, pro forma net income (loss) for the quarter ending 2017-09-30 was -$2.79M.
- Eledon Pharmaceuticals, Inc. business acquisition, pro forma net income (loss) for the quarter ending 2017-06-30 was -$3.26M.
- Eledon Pharmaceuticals, Inc. business acquisition, pro forma net income (loss) for the quarter ending 2017-03-31 was -$3.63M.
- Eledon Pharmaceuticals, Inc. business acquisition, pro forma net income (loss) for fiscal 2017 was -$11.79M.
- Eledon Pharmaceuticals, Inc. business acquisition, pro forma net income (loss) for fiscal 2016 was -$42.42M.
| Period end | Business Acquisition, Pro Forma Net Income (Loss) 3 month | Business Acquisition, Pro Forma Net Income (Loss) 6 month | Business Acquisition, Pro Forma Net Income (Loss) 9 month | Business Acquisition, Pro Forma Net Income (Loss) 12 month |
|---|---|---|---|---|
| 2017-12-31 | -$2.11M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-28 | -$4.90M derived: sum of 2 quarters · filed 2019-03-28 | -$8.16M derived: sum of 3 quarters · filed 2019-03-28 | -$11.79M 10-K · filed 2019-03-28 |
| 2017-09-30 | -$2.79M 10-Q · filed 2018-11-13 | -$6.05M derived: sum of 2 quarters · filed 2018-11-13 | -$9.68M 10-Q · filed 2018-11-13 | -$14.26M derived: sum of 4 quarters · filed 2018-11-13 |
| 2017-06-30 | -$3.26M 10-Q · filed 2018-08-07 | -$6.89M 10-Q · filed 2018-08-07 | -$11.47M derived: sum of 3 quarters · filed 2018-08-07 | -$22.25M derived: sum of 4 quarters · filed 2018-08-07 |
| 2017-03-31 | -$3.63M 10-Q · filed 2018-05-11 | -$8.21M derived: sum of 2 quarters · filed 2018-05-11 | -$19.00M derived: sum of 3 quarters · filed 2018-05-11 | -$33.52M derived: sum of 4 quarters · filed 2018-05-11 |
| 2016-12-31 | -$4.58M derived: 10-K 12 month − 10-Q 9 month · filed 2018-04-02 | -$15.37M derived: sum of 2 quarters · filed 2018-04-02 | -$29.89M derived: sum of 3 quarters · filed 2018-04-02 | -$42.42M 10-K · filed 2018-04-02 |
| 2016-09-30 | -$10.79M 10-Q · filed 2017-11-08 | -$25.32M derived: sum of 2 quarters · filed 2017-11-08 | -$37.84M 10-Q · filed 2017-11-08 | |
| 2016-06-30 | -$14.53M 10-Q · filed 2017-08-09 | -$27.06M 10-Q · filed 2017-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |